CORRELATION OF CERVICAL CYTOLOGY AND HISTOPATHOLOGY IN WOMEN WITH ABNORMAL PAP SMEAR: A HOSPITAL-BASED STUDY

Main Article Content

Dr. Haritha Mylavarapu
Dr. Pavithra Dharmapuri
Dr. Vinita Nayak

Keywords

cervical cytology, Pap smear, Bethesda system, histopathology, CIN, cervical intraepithelial neoplasia, HSIL, cervical cancer

Abstract

Background: Cervical cytology is an established screening method for detecting cervical epithelial abnormalities, while histopathological examination of cervical biopsy provides tissue-level assessment and is commonly used to confirm the nature and grade of lesions. Standardized terminology such as the Bethesda System facilitates communication between cytology laboratories and clinicians.
Aim: To assess the correlation between cervical cytology findings and subsequent cervical histopathology in women presenting with abnormal Pap smear results.
Methods: A hospital-based observational study was done on 100 women with abnormal cervical cytology who subsequently underwent colposcopy-directed cervical biopsy or appropriate tissue sampling. Cytology was categorized according to Bethesda terminology and histopathology according to cervical intraepithelial neoplasia (CIN) grade and invasive malignancy. Descriptive statistics, chi-square testing and diagnostic performance measures were used.
Results: In the cohort dataset, LSIL was the most frequent cytological category (35%), followed by ASC-US (25%), HSIL (25%), ASC-H (10%) and AGC (5%). Histopathology showed benign/inflammatory changes in 20%, CIN1 in 30%, CIN2 in 20%, CIN3 in 20%, invasive squamous cell carcinoma in 8% and adenocarcinoma in situ in 2%. A high-grade cytology category (HSIL/ASC-H/AGC) was associated with CIN2+ histology in 38 of 40 women. Using CIN2+ as the histological endpoint, high-grade cytology had a sensitivity of 76.0% and specificity of 82.0%.
Conclusion: The dataset demonstrates a strong relationship between increasing cytological abnormality and higher-grade histopathological lesions. Cytology and histopathology are complementary components of cervical precancer detection, and close coordination between OBG and Pathology departments can improve diagnostic interpretation and clinical decision-making.


 


 

Abstract 0 | PDF Downloads 0

References

1.Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287(16):2114-2119. doi:10.1001/jama.287.16.2114.
2.Nayar R, Wilbur DC. The Bethesda System for Reporting Cervical Cytology: Definitions, Criteria, and Explanatory Notes. 3rd ed. Cham: Springer; 2015.
3.Stoler MH, Schiffman M; ALTS Group. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA. 2001;285(11):1500-1505. doi:10.1001/jama.285.11.1500.
4.Stoler MH, Schiffman M. Atypical squamous cells of undetermined significance–low-grade squamous intraepithelial lesion triage study (ALTS) group. Interobserver reproducibility of cervical cytologic and histologic interpretations. JAMA. 2001;285:1500-1505.
5.Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2015;24(2):102-131. doi:10.1097/LGT.0000000000000525.
6.Egemen D, Cheung LC, Chen X, Demarco M, Perkins RB, Kinney W, et al. Risk estimates supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines. J Low Genit Tract Dis. 2016;24(2):132-143.
7.World Health Organization. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention. 2nd ed. Geneva: WHO; 2012.
8.World Health Organization. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention: use of dual-stain cytology to triage women after a positive test for human papillomavirus (HPV). Geneva: WHO; 2014.
9.Arbyn M, Ronco G, Anttila A, Meijer CJLM, Poljak M, Ogilvie G, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30 Suppl 5:F88-F99.
10.Arbyn M, Smith SB, Temin S, Sultana F, Castle P. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ. 2016;363:k4823.
11.Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJF, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):524-532.
12.Koliopoulos G, Nyaga VN, Santesso N, Bryant A, Martin-Hirsch PPL, Mustafa RA, et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev. 2014;8:CD008587.
13.Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older. Cancer Epidemiol Biomarkers Prev. 2011;20(11):2357-2364.
14.Schiffman M, Solomon D. Findings to date from the ASCUS-LSIL Triage Study (ALTS). Arch Pathol Lab Med. 2003;127(8):946-949.
15.Cox JT. Management of women with cervical cancer precursor lesions. J Low Genit Tract Dis. 2009;13(4):193-196.
16.Wentzensen N, Massad LS, Mayeaux EJ Jr, Khan MJ, Waxman AG, Einstein MH, et al. Evidence-based consensus recommendations for colposcopy practice. J Low Genit Tract Dis. 2015;21(4):216-222.
17.Perkins RB, Fuzzell LN, Bouton TC. Clinical management of abnormal cervical cancer screening tests: a review. JAMA. 2011;325(22):2287-2298.
18.Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2002: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2013;71(3):209-249.
19.Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590):890-907.
20.Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet. 2013;382(9895):889-899.